title: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
abstract: OBJECTIVE
  The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours' (NETs) treatment.
  
  
  METHODS
  Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts).
  
  
  RESULTS
  In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively.
  
  
  CONCLUSIONS
  The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues.
authors.affiliation: S.C. Oncologia Medica 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian, 1, Milan 20133, Italy. emilio.bajetta@istitutotumori.mi.it
authors.forename: Emilio
authors.initials: E
authors.lastname: Bajetta
authors.forename: Laura
authors.initials: L
authors.lastname: Catena
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
authors.forename: Sara
authors.initials: S
authors.lastname: De Dosso
authors.forename: Ettore
authors.initials: E
authors.lastname: Bichisao
authors.forename: Leonardo
authors.initials: L
authors.lastname: Ferrari
authors.forename: Antonia
authors.initials: A
authors.lastname: Martinetti
authors.forename: Marco
authors.initials: M
authors.lastname: Platania
authors.forename: Elena
authors.initials: E
authors.lastname: Verzoni
authors.forename: Barbara
authors.initials: B
authors.lastname: Formisano
authors.forename: Roberto
authors.initials: R
authors.lastname: Bajetta
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D000069287:Capecitabine; D053379:Chromogranin A / Q000097:blood; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077150:Oxaliplatin; D010071:Oxaloacetates; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D053379:Chromogranin A; D004338:Drug Combinations; D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil